首页> 外文期刊>World Journal of Gastroenterology >Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, protects pancreas against acute cerulein-induced pancreatitis
【24h】

Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, protects pancreas against acute cerulein-induced pancreatitis

机译:吡格列酮是过氧化物酶体增殖物激活的受体-γ的特定配体,可保护胰腺免受急性小分子诱导的胰腺炎

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: To determine the effect of pioglitazone, a specific peroxisome proliferator-activated receptor-γ (PPARγ) ligand, on the development of acute pancreatitis (AP) and on the expression of heat shock protein 70 (HSP70) in the pancreas. METHODS: AP was induced in rats by subcutaneous infusion of cerulein for 5 h. Pancreatic blood flow was measured by laser Doppler flowmetry. Plasma lipase activity, interleukin-1β (IL-1β) and IL-10 were determined. Pancreatic weight and histology were evaluated and pancreatic DNA synthesis and blood flow as well as pancreatic mRNA for IL-1β and HSP70 were assessed in rats treated with pioglitazone alone or in combination with cerulein. RESULTS: Pioglitazone administered (10-100 mg/kg i.g.) 30 min before cerulein, attenuated dose-dependently the pancreatic tissue damage in cerulein-induced pancreatitis (CIP) as demonstrated by the improvement of pancreatic histology, reduction in plasma lipase activity, plasma concentration of pro-inflammatory IL-1β and its gene expression in the pancreas and attenuation of the pancreatitis-evoked fall in pancreatic blood flow. CIP increased pancreatic HSP70 mRNA and protein expression in the pancreas and this effect was enhanced by pioglitazone treatment. CONCLUSION: Pioglitazone attenuates CIP and the beneficial effect of this pioglitazone is multifactorial probably due to its anti-inflammatory activities, to the suppression of IL-1β and to the overexpression of HSP70. PPARγ ligands could represent a new therapeutic option in the treatment of AP.
机译:目的:确定吡格列酮(一种特定的过氧化物酶体增殖物激活受体-γ(PPARγ)配体)对急性胰腺炎(AP)的发展以及胰腺热休克蛋白70(HSP70)表达的影响。方法:皮下注射铜蓝蛋白5 h诱导大鼠AP。通过激光多普勒血流仪测量胰腺血流。测定血浆脂肪酶活性,白介素-1β(IL-1β)和IL-10。在单独使用吡格列酮或与青霉素联合治疗的大鼠中,评估了胰腺的重量和组织学,评估了胰腺DNA的合成,血流以及IL-1β和HSP70的胰腺mRNA。结果:在青霉素之前30分钟给予吡格列酮(10-100 mg / kg ig),剂量依赖性地减轻了青霉素引起的胰腺炎(CIP)对胰腺组织的损害,这通过改善胰腺组织学,降低血浆脂肪酶活性,血浆来证明胰腺中促炎性IL-1β的高浓度及其基因表达以及胰腺炎引起的胰腺血流下降的减弱。 CIP增加胰腺中胰腺HSP70 mRNA和蛋白表达,吡格列酮治疗可增强这种作用。结论:吡格列酮可减弱CIP,该吡格列酮的有益作用是多因素的,可能是由于其抗炎活性,IL-1β的抑制和HSP70的过度表达。 PPARγ配体可能代表AP治疗的新治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号